These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 9548506)

  • 1. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
    Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
    J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
    Chen J; Zhou JH; Ball ED
    Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils.
    van Spriel AB; van den Herik-Oudijk IE; van Sorge NM; Vilé HA; van Strijp JA; van de Winkel JG
    J Infect Dis; 1999 Mar; 179(3):661-9. PubMed ID: 9952373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
    Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
    Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
    van Egmond M; van Spriel AB; Vermeulen H; Huls G; van Garderen E; van de Winkel JG
    Cancer Res; 2001 May; 61(10):4055-60. PubMed ID: 11358825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
    Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
    J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
    J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
    van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
    Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma.
    Honeychurch J; Tutt AL; Valerius T; Heijnen IA; Van De Winkel JG; Glennie MJ
    Blood; 2000 Nov; 96(10):3544-52. PubMed ID: 11071653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
    Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
    Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
    Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
    Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
    Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
    Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.